Edward Jones Upgrades Zimmer Biomet Holdings, Inc. (ZBH) to “Buy”

Edward Jones upgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat Ratings reports.

Other analysts have also issued reports about the company. Royal Bank Of Canada reaffirmed an outperform rating and issued a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reissued a buy rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Wells Fargo & Company reissued a market weight rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the stock a buy rating in a research note on Friday, July 28th. Finally, Stifel Nicolaus reissued a hold rating and set a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $134.00.

Shares of Zimmer Biomet Holdings (ZBH) opened at $110.75 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The stock has a market capitalization of $22,423.90, a P/E ratio of 13.72, a PEG ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings has a 12 month low of $95.63 and a 12 month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.79 earnings per share. research analysts predict that Zimmer Biomet Holdings will post 8.03 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Edward Jones Upgrades Zimmer Biomet Holdings, Inc. (ZBH) to “Buy”” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/13/edward-jones-upgrades-zimmer-biomet-holdings-inc-zbh-to-buy.html.

Several hedge funds have recently bought and sold shares of ZBH. JPMorgan Chase & Co. raised its holdings in shares of Zimmer Biomet Holdings by 92.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after buying an additional 1,577,874 shares during the period. Harbour Capital Advisors LLC raised its holdings in shares of Zimmer Biomet Holdings by 13,131.3% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after buying an additional 1,292,773 shares during the period. Longview Partners Guernsey LTD raised its holdings in shares of Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares during the period. Koch Industries Inc. raised its holdings in shares of Zimmer Biomet Holdings by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of Zimmer Biomet Holdings by 230.3% in the 1st quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock valued at $128,643,000 after buying an additional 734,500 shares during the period. Hedge funds and other institutional investors own 85.44% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply